Gyre Therapeutics, Inc. (GYRE)
Nasdaq: GYRE · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2002
Grade5.2
◀ Past 4.5● Present 5.9▶ Future 4.9
Filings
464 filings since 2017 beside 328 insider forms · Accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextAccelerated filer and smaller reporting company
10-K
Annual report for the fiscal year ending Dec 31, 2026Accelerated filers have 75 days after the fiscal year ends.
by Mar 16, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 36 days after the quarter ended. The proxy statement was last filed Apr 27, 2026.
Filings a yearinsider forms included
7490869893757367
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 12 times in the last 36 months, the newest Oct 22, 2026.Listing warning from its exchange (8-K item 3.01): 3 times in the last 36 months, the newest Jul 5, 2024.SEC letters: 2 in the last 36 months, the newest Nov 20, 2024.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 5, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Jul 16, 2026
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Jul 10, 2026
May 4, 2026
8-K items 2.01, 3.02, 3.03, 5.02, 5.03, 7.01, 9.01
Purchase or sale of a business completed; Shares sold without registration; Change to shareholders' rights; Officer or director change; Charter, bylaw or fiscal-year change; Investor disclosure (Regulation FD) · Current report
Mar 2, 2026
8-K items 1.01, 3.02, 5.02, 5.03, 7.01, 9.01
Major agreement signed; Shares sold without registration; Officer or director change; Charter, bylaw or fiscal-year change; Investor disclosure (Regulation FD) · Current report
Aug 22, 2025
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Aug 18, 2025
40 of 464 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.